{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:41:23Z","timestamp":1787586083760,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01413-7","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T13:01:46Z","timestamp":1765026106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2641-1425","authenticated-orcid":false,"given":"Jo\u00e3o Tadeu Damian","family":"Souto Filho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Oliveira","family":"Cantadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-4731","authenticated-orcid":false,"given":"Edvan de Queiroz","family":"Crusoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-9548","authenticated-orcid":false,"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"1413_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Prim. 2024;10:45.","journal-title":"Nat Rev Dis Prim"},{"key":"1413_CR2","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1080\/14796694.2024.2342228","volume":"20","author":"R Fonseca","year":"2024","unstructured":"Fonseca R, Rossi A, Medhekar R, Voelker J, Homan T, Wilcock J, et al. Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel. Future Oncol. 2024;20:1645\u201356.","journal-title":"Future Oncol"},{"key":"1413_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"1413_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906\u201317.","journal-title":"N Engl J Med"},{"key":"1413_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906\u201317.","journal-title":"N Engl J Med"},{"key":"1413_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519\u201327.","journal-title":"Lancet"},{"key":"1413_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","volume":"127","author":"NWCJ van de Donk","year":"2016","unstructured":"van de Donk NWCJ, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127:681\u201395.","journal-title":"Blood"},{"key":"1413_CR8","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"1413_CR9","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104\u201315.","journal-title":"N Engl J Med"},{"key":"1413_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025;31:1195\u2013202.","journal-title":"Nat Med"},{"key":"1413_CR11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos M-A, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:1597\u2013609.","journal-title":"N Engl J Med"},{"key":"1413_CR12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"M-V Mateos","year":"2018","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518\u201328.","journal-title":"N Engl J Med"},{"key":"1413_CR13","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.4. Cochrane; 2023. www.training.cochrane.org\/handbook."},{"key":"1413_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1413_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"1413_CR16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1413_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"1413_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.","journal-title":"BMC Med Res Methodol"},{"key":"1413_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1413_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21:111.","journal-title":"BMC Med Res Methodol"},{"key":"1413_CR21","volume":"13","author":"A Messori","year":"2021","unstructured":"Messori A. Synthetizing published evidence on survival by reconstruction of patient-level data and generation of a multi-trial Kaplan-Meier curve. Cureus. 2021;13:e19422.","journal-title":"Cureus"},{"key":"1413_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:53.","journal-title":"Blood Cancer J"},{"key":"1413_CR23","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:1582\u201396.","journal-title":"Lancet Oncol"},{"key":"1413_CR24","first-page":"1723","volume":"8","author":"T Facon","year":"2024","unstructured":"Facon T, Kumar SK, Orlowski RZ, Bahlis N, Moreau P, Goldschmidt H, et al. Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study. HemaSphere. 2024;8:1723\u20135.","journal-title":"HemaSphere"},{"key":"1413_CR25","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","volume":"39","author":"T Facon","year":"2025","unstructured":"Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, et al. Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39:942\u201350.","journal-title":"Leukemia"},{"key":"1413_CR26","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1200\/JCO.2025.43.16_suppl.7516","volume":"43","author":"T Facon","year":"2025","unstructured":"Facon T, Zweegman S, Hungria V, Bahlis NJ, Venner CP, Braunstein MJ, et al. Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study. JCO. 2025;43:7516.","journal-title":"JCO"},{"key":"1413_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jgo.2020.12.001","volume":"12","author":"SJ Grant","year":"2021","unstructured":"Grant SJ, Mian HS, Giri S, Boutin M, Dottorini L, Neuendorff NR, et al. Transplant-ineligible newly diagnosed multiple myeloma: current and future approaches to clinical care: a Young International Society of Geriatric Oncology Review Paper. J Geriatr Oncol. 2021;12:499\u2013507.","journal-title":"J Geriatr Oncol"},{"key":"1413_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00779-2","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian H, McCurdy A, Giri S, Grant S, Rochwerg B, Winks E, et al. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Blood Cancer J. 2023;13:6.","journal-title":"Blood Cancer J"},{"key":"1413_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00988-x","volume":"14","author":"IV Kostopoulos","year":"2024","unstructured":"Kostopoulos IV, Fotiou D, Gavriatopoulou M, Rousakis P, Ntanasis-Stathopoulos I, Panteli C, et al. Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity. Blood Cancer J. 2024;14:26.","journal-title":"Blood Cancer J"},{"key":"1413_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1182\/hematology.2020000109","volume":"2020","author":"NWCJ van de Donk","year":"2020","unstructured":"van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program. 2020;2020:248\u201358.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1413_CR31","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s12325-024-02807-y","volume":"41","author":"BGM Durie","year":"2024","unstructured":"Durie BGM, Kumar SK, Ammann EM, Fu AZ, Kaila S, Lam A, et al. Adjusted indirect treatment comparison of progression-free survival with D-Rd and VRd based on MAIA and SWOG S0777 individual patient-level data. Adv Ther. 2024;41:1923\u201337.","journal-title":"Adv Ther"},{"key":"1413_CR32","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Kumar SK, Usmani SZ, Nonyane BAS, Ammann EM, Lam A, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95:1486\u201394.","journal-title":"Am J Hematol"},{"key":"1413_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clml.2023.09.003","volume":"24","author":"LN Gordan","year":"2024","unstructured":"Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, et al. Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study. Clin Lymphoma Myeloma Leuk. 2024;24:55\u201363.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1413_CR34","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s12325-022-02083-8","volume":"39","author":"T Facon","year":"2022","unstructured":"Facon T, San-Miguel J, Dimopoulos MA, Mateos M-V, Cavo M, van Beekhuizen S, et al. Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: a systematic literature review and network meta-analysis. Adv Ther. 2022;39:1976\u201392.","journal-title":"Adv Ther"},{"key":"1413_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1286029","volume":"14","author":"W Tang","year":"2024","unstructured":"Tang W, Zhang L, Zheng Y, Pan L, Niu T. Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review. Front Oncol. 2024;14:1286029.","journal-title":"Front Oncol"},{"key":"1413_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103504","volume":"168","author":"S Kiss","year":"2021","unstructured":"Kiss S, Gede N, So\u00f3s A, Hegyi P, Nagy B, Imrei M, et al. Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: a network meta-analysis. Crit Rev Oncol Hematol. 2021;168:103504.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1413_CR37","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jgo.2020.05.013","volume":"11","author":"S Giri","year":"2020","unstructured":"Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, et al. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: a systematic review and meta-analysis. J Geriatr Oncol. 2020;11:1285\u201392.","journal-title":"J Geriatr Oncol"},{"key":"1413_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/ejh.13407","volume":"105","author":"MD Gil-Sierra","year":"2020","unstructured":"Gil-Sierra MD, Gimeno-Ballester V, Fenix-Caballero S, Alegre-Del Rey EJ. Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients. Eur J Haematol. 2020;105:56\u201365.","journal-title":"Eur J Haematol"},{"key":"1413_CR39","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1080\/10428194.2019.1683736","volume":"61","author":"K Ramasamy","year":"2020","unstructured":"Ramasamy K, Dhanasiri S, Thom H, Buchanan V, Robinson S, D\u2019Souza VK, et al. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leuk Lymphoma. 2020;61:668\u201379.","journal-title":"Leuk Lymphoma"},{"key":"1413_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01253-5","volume":"15","author":"JTD Souto Filho","year":"2025","unstructured":"Souto Filho JTD, Cantadori LO, Crusoe de EQ, Hungria V, Maiolino A. Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Cancer J. 2025;15:37.","journal-title":"Blood Cancer J"},{"key":"1413_CR41","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","volume":"8","author":"MS Ebraheem","year":"2024","unstructured":"Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024;8:5993\u20136002.","journal-title":"Blood Adv"},{"key":"1413_CR42","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3390\/cancers16172938","volume":"16","author":"B Paul","year":"2024","unstructured":"Paul B, Anwer F, Raza S, Mammadzadeh A, Khasawneh B, Shatnawi S, et al. Comparative meta-analysis of triplet vs. quadruplet induction regimens in newly diagnosed, treatment na\u00efve, multiple myeloma. Cancers. 2024;16:2938.","journal-title":"Cancers"},{"key":"1413_CR43","doi-asserted-by":"crossref","unstructured":"Mateos M-V, San-Miguel J, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2025;26:S1470-2045(25)00018-X.","DOI":"10.1016\/S1470-2045(25)00018-X"},{"key":"1413_CR44","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.clml.2023.01.016","volume":"23","author":"J C\u00f4t\u00e9","year":"2023","unstructured":"C\u00f4t\u00e9 J, Kotb R, Bergstrom DJ, LeBlanc R, Mian HS, Othman I, et al. First line treatment of newly diagnosed transplant ineligible multiple myeloma: recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. Clin Lymphoma Myeloma Leuk. 2023;23:340\u201354.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1413_CR45","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","volume":"30","author":"X Leleu","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30:2235\u201341.","journal-title":"Nat Med"},{"key":"1413_CR46","volume":"15","author":"A Messori","year":"2023","unstructured":"Messori A, Fadda V, Romeo MR, Veneziano S, Trippoli S. A comparison of statistical analysis between \u201cReal\u201d patients reported in Kaplan-Meier curves and \u201cReconstructed\u201d patients estimated through the IPDfromKM method: analysis of eight trials evaluating catheter ablation of ventricular tachycardia. Cureus. 2023;15:e47891.","journal-title":"Cureus"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01413-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01413-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01413-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T13:01:47Z","timestamp":1765026107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01413-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01413-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JTDSF reported receiving honoraria from AbbVie, AstraZeneca, BeOne, BMS, Johnson & Johnson, Novartis, and Sanofi. LOC reported receiving honoraria from Johnson & Johnson. EQC reported receiving research funding from Johnson & Johnson and honoraria from Amgen, BMS, Johnson & Johnson, Sanofi, GSK, and Takeda. VH reported receiving honoraria from BMS, GSK, Johnson & Johnson, Regeneron, Sanofi, Takeda, Amgen, and AbbVie. AM reported receiving honoraria from Johnson & Johnson, BMS, Sanofi, Takeda, Pfizer, and Amgen. No other disclosures were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}